Skip to main content

Table 3 Treatment-emergent adverse events (%) with significant treatment-by-tiredness subgroup interaction

From: Effect of duloxetine in patients with fibromyalgia: tiredness subgroups

 

P-value (treatment-by-tiredness subgroup)

Mild subgroup

Moderate subgroup

Severe subgroup

  

Placebo

(n = 20)

(%)

Duloxetine

(n = 29)

(%)

Placebo

(n = 83)

(%)

Duloxetine

(n = 133)

(%)

Placebo

(n = 430)

(%)

Duloxetine

(n = 634)

(%)

Patients with ≥1 TEAE

0.040

90.0

96.6

73.5

91.0

77.7

82.0

Hypoaesthesia

0.094

10.0

0.0

1.2

1.5

1.2

2.1

Arthralgia

0.008

10.0

0.0

9.6

2.3

2.8

3.8

Cough

0.034

15.0

0.0

1.2

3.0

2.6

3.2

Myalgia

0.081

10.0

3.5

0.0

3.8

1.6

3.3

Bronchitis

0.014

5.0

0.0

3.6

0.0

2.3

3.3

Influenza

0.019

0.0

3.5

6.0

0.8

1.4

2.5

Palpitations

0.085

0.0

3.5

4.8

1.5

2.5

1.2

Restless leg syndrome

0.030

5.0

0.0

0.0

3.0

1.4

0.6

Osteoarthritis

0.029

10.0

0.0

3.6

0.0

0.7

0.8

  1. TEAE, treatment-emergent adverse event.